A detailed history of Bank Of America Corp transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 995,069 shares of APLS stock, worth $29.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
995,069
Previous 723,444 37.55%
Holding current value
$29.8 Million
Previous $42.5 Million 10.24%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $10.3 Million - $16.2 Million
271,625 Added 37.55%
995,069 $38.2 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $16 Million - $21 Million
289,107 Added 66.56%
723,444 $42.5 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $909,744 - $1.59 Million
24,495 Added 5.98%
434,337 $26 Million
Q2 2023

Aug 14, 2023

SELL
$76.68 - $93.31 $15.2 Million - $18.5 Million
-197,893 Reduced 32.56%
409,842 $37.3 Million
Q1 2023

May 12, 2023

BUY
$46.59 - $66.96 $6.46 Million - $9.29 Million
138,723 Added 29.58%
607,735 $40.1 Million
Q4 2022

Feb 10, 2023

SELL
$43.24 - $61.04 $9.64 Million - $13.6 Million
-222,865 Reduced 32.21%
469,012 $24.3 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $14.5 Million - $22.5 Million
323,561 Added 87.85%
691,877 $47.3 Million
Q2 2022

Aug 12, 2022

SELL
$35.07 - $59.21 $478,424 - $807,742
-13,642 Reduced 3.57%
368,316 $16.7 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $3.8 Million - $5.79 Million
107,052 Added 38.94%
381,958 $19.4 Million
Q4 2021

Feb 08, 2022

SELL
$30.74 - $49.16 $155,728 - $249,044
-5,066 Reduced 1.81%
274,906 $13 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $1.24 Million - $2.77 Million
39,593 Added 16.47%
279,972 $9.23 Million
Q2 2021

Sep 13, 2021

BUY
$40.9 - $64.9 $9.83 Million - $15.6 Million
240,379 New
240,379 $15.2 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.29B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.